Basic HTML Version
© The Canadian Journal of Urology™; 18(Supplement 1); April 2011
References
1. Gittens PR, Lallas CD, Pe ML, Perkel R, Folia C, Gomella LG.
Uropharmacology for the primary care physician.
Can J Urol
2008; 15(Suppl 1):78-91;discussion 91.
2. Gomella LG, Lallas CD, Perkel R, Folia C, Hirsch I, DasA, Shenot
P. Uropharmacology in primary care: 2010 update.
Can J Urol
2010; 17(Suppl 1):35-51.
3. Auffenberg G, Helfan B, McVary K. Established medical
therapy for benign prostate hyperplasia.
Urol Clin North Am
2009;36(4):443-459.
4. Laborde EE, McVary KT. Medical management of lower urinary
tract symptoms.
Rev Urol
2009;11(Suppl 1):S19-S25.
5. Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary
care: what you need to know.
J Urol
2006;175(3 Pt 2):S19-S24.
6. Bushman W. Etiology, epidemiology, and natural history of
benign prostatic hyperplasia.
Urol Clin North Am
2009;36(4):403-
415.
7. Lepor H. Pathophysiology of benign prostatic hyperplasia:
insights from medical therapy for the disease.
Rev Urol
2009;11(Suppl 1):S9-S13.
8. Van Hest P, D’Ancona F. Update inminimal invasive therapy in
benign prostatic hyperplasia.
Minerva Urol Nefrol
2009;61(3):257-
268.
9. Roehrborn CG. Efficacy of alpha-adrenergic receptor blockers
in the treatment of male lower urinary tract symptoms.
Rev Urol
2009;11(Suppl 1):S1-S8.
10.Nickel JC, Herschorn S, Corcos J et al; Canadian Prostate
Health Council; Canadian Urological Association Guidelines
Committee. Canadian guidelines for the management of
benign prostatic hyperplasia.
Can J Urol
2005;12(3):2677-
2683.
11. McVary KT, Roehrborn CG, Avins AL et al. Update on AUA
guideline on the management of benign prostatic hyperplasia.
J Urol
2011;185:1794-1804.
12. Kaplan SA. Side effects of alpha-blocker use: retrograde
ejaculation.
Rev Urol
2009;11(Suppl 1):S14-S18.
13. Issa SA, Hadid OH, Baylis O, Dayan M. Alpha antagonists
and intraoperative floppy iris syndrome: A spectrum.
Clin
Ophthalmol
2008;2(4):735-741.
14. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An
overviewon 5alpha-reductase inhibitors.
Steroids
2010;75(2):109-
153.
15. MemisA, Ozden C, Ozdal OL, Guzel O, Han O, Seckin S. Effect
of finasteride treatment on suburethral prostatic microvessel
density in patients with hematuria related to benign prostate
hyperplasia.
Urol Int
2008;80(2):177-180.
16. Thompson IM, Goodman PJ, Tangen CM et al. The influence
of finasteride on the development of prostate cancer.
N Engl J
Med
2003;349(3):215-224.
17. Gomella LG. Chemoprevention using dutasteride: the REDUCE
trial.
Curr Opin Urol
2005;15(1):29-32.
18.Andriole GL, Bostwick D, Brawley O et al. The influence
of dutasteride on the risk of biopsy-detectable prostate
cancer: outcomes of the REduction by DUtasteride of
prostate Cancer Events (REDUCE) study.
N Engl J Med
2010;362(13):1192-1202.
19. McConnell JD, Bruskewitz R, Walsh P et al. The effect of
finasteride on the risk of acute urinary retention and the
need for surgical treatment among men with benign prostatic
hyperplasia. Finasteride Long-Term Efficacy and Safety Study
Group.
N Engl J Med
1998;338(9):557-563.
20. Roehrborn CG, Siami P, Barkin J et al. CombAT Study Group.
The effects of dutasteride, tamsulosin and combination therapy
on lower urinary tract symptoms in men with benign prostatic
hyperplasia and prostatic enlargement: 2-year results from the
CombAT study.
J Urol
2008;179(2):616-621.
21. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ,
McKinlay JB. Impotence and its medical and psychosocial
correlates: results of the Massachusetts Male Aging Study.
J
Urol
1994;151(1):54-61.
22. Grover SA, Lowensteyn I, Kaouache M et al. The prevalence
of erectile dysfunction in the primary care setting.
Arch Intern
Med
2006;166:213-219.
23. Lue TF. Erectile dysfunction.
N Engl J Med
2000;342(24):1802-
1813.
24. Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi
L. Which patients with sexual dysfunction are suitable
for testosterone replacment therapy?
J Endocrinol Invest
2007;30(10):880-888.
25. Eardley I, Donatucci C, Corbin J et al. Pharmacotherapy for
erectile dysfunction.
J Sex Med
2010;7(1 Pt 2):524-540.
26. Seftel AD, Farber J, Fletcher J et al. A three-part study to
investigate the incidence and potential etiologies of tadalafil-
associated back pain ormyalgia.
Int J Impot Res
2005;17(5):455-461.
27.Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J.
Safety, efficacy, and pharmacokinetic overview of low-dose
daily administration of tadalafil.
J Sex Med
2009;6(7):2039-2048.
28. Mathews MK. Nonarteritic anterior ischemic optic neuropathy.
Curr Opin Ophthalmol
2005;16(6):341-345.
29. Heidelbaugh JJ. Management of erectile dysfunction.
Am Fam
Physician
2010;81(3):305-312.
30. Montorsi F, Salonia A, Deho F et al. Pharmacological
management of erectile dysfunction.
BJU Int
2003;91(5):446-454.
31. Hatzimouratidis K, Hatzichristou DG. A comparative review
of the options for treatment of erectile dysfunction: which
treatment for which patient?
Drugs
2005;65(12):1621-1650.
32. MoralesA, Buvat J, Gooren LJ et al. Endocrine aspects of sexual
dysfunction in men.
J Sex Med
2004;1(1):69-81.
33. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman
MR. Longitudinal effects of aging on serum total and free
testosterone levels in healthy men. Baltimore Longitudinal
Study of Aging.
J Clin Endocrinol Metab
2001;86(2):724-731.
34. Seftel AD, Mack RJ, SecrestAR, Smith TM. Restorative increases
in serum testosterone levels are significantly correlated to
improvements in sexual functioning.
J Androl
2004;25(6):963-972.
35.Wang C, Swerdloff RS, Iranmanesh A et al. Transdermal
testosterone gel improves sexual function, mood, muscle
strength, and body composition parameters in hypogonadal
men.
J Clin Endocrinol Metab
2000;85(8):2839-2853.
36. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R.
AA2500 testosterone gel normalizes androgen levels in aging
males with improvements in body composition and sexual
function.
J Clin Endocrinol Metab
2003;88(6):2673-2681.
37. Bagatell CJ, Bremner WJ. Androgens in men--uses and abuses.
N Engl J Med
1996;334(11):707-714.
38. Jockenhovel F. Testosterone therapy--what, when and towhom?
Aging Male
2004;7(4):319-324.
39. Lazarou S, Morgentaler A. Hypogonadism in the man with
erectile dysfunction: what to look for and when to treat.
Curr
Urol Rep
2005;6(6):476-481.
40. Gooren LJ. Advances in testosterone replacement therapy.
Front
Horm Res
2009;37:32-51.
41. Korbonits M, Kipnes M, Grossman AB. Striant SR: a novel,
effective and convenient testosterone therapy for male
hypogonadism.
Int J Clin Pract
2004;58(11):1073-1080.
42. Morgentaler A. Rapidly shifting concepts regarding androgens
and prostate cancer.
Scientific World Journal
2009;27(9):685-690.
43. ErdemN, Chu FM. Management of overactive bladder and urge
urinary incontinence in the elderly patient.
Am J Med
2006;119(3
Suppl 1):29-36.
44. BradingAF.Amyogenic basis for the overactive bladder.
Urology
1997;50(6A Suppl):57-67.
45. Ouslander JG. Management of overactive bladder.
N Engl J Med
2004;350(8):786-799.
37
Pharmacology for common urologic diseases: 2011 review for the primary care physician